Repros Therapeutics Inc(NASDAQ:RPRX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Earnings per share were $-0.18. Analysts had estimated an EPS of $-0.20.
Repros Therapeutics Inc (RPRX) shares turned negative on Wednesdays trading session with the shares closing down -0.05 points or -2.33% at a volume of 1,61,247. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.13. The peak price level was also seen at $2.13 while the days lowest was $2.04. Finally the shares closed at $2.1. The 52-week high of the shares is $8.959 while the 52-week low is $0.8. According to the latest information available, the market cap of the company is $51 M.
Several Insider Transactions has been reported to the SEC. On Feb 19, 2016, Joseph Podolski (CEO) purchased 10,000 shares at $0.93 per share price.Also, On Jan 28, 2016, J. F. Wernicke (Chief Medical Officer) purchased 10,000 shares at $1.12 per share price.On Jan 28, 2016, Katherine Anderson (CFO) purchased 12,000 shares at $1.08 per share price, according to the Form-4 filing with the securities and exchange commission.
Repros Therapeutics Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound which is developed for the treatment of secondary hypogonadism in overweight men. The Company’s Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.